6,856
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Early effects of selective serotonin reuptake inhibitors (SSRIs) on cornea and lens density in patients with depression

, , , &
Pages 387-393 | Received 20 Jun 2019, Accepted 26 Sep 2019, Published online: 11 Oct 2019

References

  • WHO. Fact Sheet. 22nd March 2018.
  • Cetin M, Acikel C. In perspective of meta-analyses: are all of the antidepressants similar? Bul Clin Psychopharmacol. 2009;19(2):87–92.
  • Akkaya C, Kırlı S, Eker S, et al. Comparison of the efficacy and safety of sertraline, reboxetine, and venlafaxine in patients with major depressive disorder: a pooled analysis of four randomized, open-label trials. Bul Clin Psychopharmacol. 2010;20:274–287. doi: 10.1080/10177833.2010.11790673
  • NICE Clinical Guidelines. CG90. Depression in adults: the treatment and management of depression in adults. Appendix 19: clinical evidence forest plots. National Collaborating Centre for Mental Health (UK). Leicester (UK): British Psychological Society; 2010.
  • Brody DJ, Pratt LA, Hughes JP. NCHS Data Brief, February 2018.
  • Balikci A, Uzun O, Erdem M, et al. Side effects that cause noncompliance to antidepressant medications in the course of outpatient treatment. Bul Clin Psychopharmacol. 2014;24(1):69–75. doi: 10.5455/bcp.20120827114140
  • Fu Y, Dai Q, Zhu L, et al. Antidepressants use and risk of cataract development: a systematic review and meta-analysis. BMC Ophthalmol. 2018;18(1):31. doi:10.1186/s12886-018-0699-0.
  • Costagliola C, Parmeggiani F, Semeraro F, et al. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. Curr Neuropharmacol. 2008;6:293–310. doi: 10.2174/157015908787386104
  • Veglio F, De Sanctis U, Schiavone D, et al. Evaluation of serotonin levels in human aqueous humor. Ophthalmologica. 1998;212:160–163. doi: 10.1159/000027268
  • Kisilevsky E, Margolin EA. Case of rapid bilateral cataract development in teenager using selective serotonin reuptake inhibitors. Can J Ophthalmol. 2014;49:e114–e115. doi: 10.1016/j.jcjo.2014.06.005
  • Becker C, Jick SS, Meier CR. Selective serotonin reuptake inhibitors and cataract risk. Ophthalmology. 2017;124(11):1635–1639. doi:10.1016/j.ophtha.2017.05.002.
  • WHO. Blindness and vision impairment prevention report. 2018.
  • Diagnostic and statistical manual of mental disorders, text revision (DSM-IV-TR). 4th ed Washington (DC): American Psychiatric Association; 2000.
  • Erie JC, Brue SM, Chamberlain AM, et al. Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: a population-based, case-control study. Am J Ophthalmol. 2014;158(1):192–197.e1. doi:10.1016/j.ajo.2014.03.006.
  • Retianl Hardisty AD, Hemmerdinger CM, Quah SA. Citalopram-associated central retinal vein occlusion. Int Ophthalmol. 2009 Aug;29(4):303–304. doi:10.1007/s10792-008-9231-5.
  • Chen HY, Lin CL, Lai SW, et al. Association of selective serotonin reuptake inhibitor use and acute angle-closure glaucoma. J Clin Psychiatry. 2016 Jun;77(6):e692–e696. doi:10.4088/JCP.15m10038.
  • Lochhead J. SSRI-associated optic neuropathy. Eye. 2015 Sep;29(9):1233–1235. doi:10.1038/eye.2015.119.
  • Eray S, Ucar HN, Vural AP. Sertraline-induced diplopia. Bul Clin Psychopharmacol. 2016;26(2):213–214. doi:10.5455/bcp.20160109124021.
  • Seitz DP, Campbell RJ, Bell CM, et al. Short-term exposure to antidepressant drugs and risk of acute angle-closure glaucoma in older adults. J Clin Psychopharmacol. 2012;32:403–407. doi: 10.1097/JCP.0b013e31825420a1
  • Health Canada. Summary safety review—antidepressants—assessing the potential risk of serious eye disorder (angle-closure glaucoma). [cited 2016 Aug 12]. Available from: http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/antidepress-eng.php.
  • Kirkham J, Seitz D. Evidence of ocular side effects of SSRIs and new warnings. Evidence Based Mental Health. 2017;20(1):27. doi:10.1136/eb-2016-102528. Epub 2016 Dec 19.
  • Costagliola C, Parmeggiani F, Sebastiani A. SSRIs and intraocular pressure modifications. CNS Drugs. 2004;18:475–484. doi: 10.2165/00023210-200418080-00001
  • Gündüz GU, Yener NP, Kılınçel O, et al. Effects of selective serotonin reuptake inhibitors on intraocular pressure and anterior segment parameters in open angle eyes. Cutan Ocul Toxicol. 2018;37(1):36–40. doi:10.1080/15569527.2017.1330270.
  • Das GK, Boriwal K, Chhabra P, et al. Presenile cataract and its risk factors: a case control study. J Family Med Prim Care. 2019;8(6):2120–2123. doi:10.4103/jfmpc.jfmpc_267_19.
  • Lindblad BE, Håkansson N, Wolk A. Smoking cessation and the risk of cataract: a prospective cohort study of cataract extraction among men. JAMA Ophthalmol. 2014;132(3):253–257. doi:10.1001/jamaophthalmol.2013.6669.
  • Aboujaoude E, Koran LM. The American psychiatric publishing textbook of psychopharmacology. 4th ed Washington (DC): American Psychiatric Publishing; 2009.
  • Zhang X, Yin Y, Yue L, et al. Selective serotonin reuptake inhibitors aggravate depression-associated dry eye via activating the NF-jB pathway. Invest Ophthalmol Vis Sci. 2019;60:407–419. doi:10.1167/iovs.18-25572.